DNA Damage-Inducing Anticancer Therapies: From Global to Precision Damage

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• DNA damage-inducing therapies, including radiotherapy and chemotherapy, are vital cancer treatments.
• The DNA damage response (DDR) network plays a critical role in managing DNA lesions, influencing repair, apoptosis, and cellular proliferation.

Purpose of the Study:

• To review the current understanding of DNA damage induction and the DDR in cancer therapy.
• To explore advancements in DNA damage-inducing therapies and targeted DDR inhibitors.
• To discuss the role of DDR in therapy response, toxicity, resistance, and combination strategies.

Main Methods:

• Literature review of DNA damage-inducing therapies and the DNA damage response.
• Analysis of current clinical developments and future directions for DDR-targeted agents.
• Examination of combination regimens involving DNA damage therapies and immunotherapy.

Main Results:

• Detailed understanding of DNA damage and DDR has improved conventional therapies.
• Targeting DDR proteins represents a promising new therapeutic strategy entering clinical practice.
• Combination therapies, including immunotherapy, can potentiate anticancer effects.

Conclusions:

• The DDR is central to the efficacy, toxicity, and resistance of DNA damage-inducing cancer therapies.
• Targeted DDR inhibition offers a novel therapeutic avenue.
• Strategic combinations of DNA damage therapies with other treatments, like immunotherapy, hold significant potential for enhanced cancer eradication.